Wed 21 Oct 2026
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Ensure the website is using the HTTPS protocol.
Registered with the Digital Government Authority under number:
| Study Title | Study Sponsor | Status | Study Drug | Trial Phase | Study Protocol Number | Site |
|---|---|---|---|---|---|---|
| Early Sedation with Dexmedetomidine vs. Placebo in Older Ventilated Critically Ill Patients A Prospective, Multi-Centre, Double-Blind, Randomized, Controlled Trial. SPICE IV | King Abdullah International Medical Research Center (KAIMRC) | Ongoing | DEXMEDETOMIDINE | 4 | SCT21R/006/04 | King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh) |
| VICTORION REAL: An international prospective Real-world study to evaluate the Effectiveness and Adherence of incLisiran plus standard of care lipid-lowering therapy compared to standard of care therapy alone in patients with primary hypercholesterolemia or mixed dyslipidemia | Novartis | Ongoing | Inclisiran | 4 | CKJX839A12 | Saud Al-Babtain Cardiac Center (Dammam) , King Salman Armed Forces Hospital(Tabuk) , King Fahd Armed Forces Hospital (Jeddah) , Dr. Sulaiman Al-Habib Medical Group Rayan (Riyadh),King Faisal Specialist Hospital and Research Center (Jeddah), Dr. Sulaiman Al-Habib Medical Group Olaya (Riyadh), International Medical Center (Jeddah) |
| The effect of novel D3 use as a mouthwash in COVID-19 patients | King Faisal Specialist Hospital and Research Center (Jeddah) | Rejected | D3 mouthwash | 4 | 2022-32 | King Faisal Specialist Hospital and Research Center (Jeddah) |
| O-SEMA-Fast: A research study to understand how oral semaglutide works in people with type 2 diabetes who plan to fast during Ramadan in the United Arab Emirates, Saudi Arabia, and Kuwait | Novo Nordisk | Ongoing | Semaglutide | 4 | NN9924-757 | Almoosa Specialist Hospital (Alahsa) |
| Study on Clinical Use of EVUSHELD (AZD7442) as Pre-exposure Prophylaxis in the Real-world Setting – A Multi-centre Observational Prospective Study to Determine the Utilisation and Clinical Outcomes of EVUSHELD in Middle East and Africa | AstraZeneca | Ongoing | EVUSHELD | 4 | D8851R0000 | King Saud Medical City (Riyadh) |
| A REGISTRY TO COLLECT CHARACTERISTICS AND OUTCOMES FROM PATIENTS WITH SOLID TUMORSPROFILED WITH A NEXT-GENERATION SEQUENCINGTEST (WAYFIND-R) | Roche | Ongoing | NA | 4 | MX39897 | King Abdulaziz Medical City NG (Riyadh) |
| Real-World Experience of Upadacitinib in Moderate to Severe Atopic Dermatitis | Abbvie | Ongoing | Upadacitinib (Rinvoq) | 4 | H23-107 | King Faisal General Hospital (Makkah), Mohammed Dossary Hospital - Al Khobar, King Fahad Central Hospital (Jazan), East Jeddah General Hospital, Hira Hospital (Makkah) , Aseer Central Hospital (Abha) |
| Articaine efficacy and safety for 3 years old children: A Clinical Randomized Control Trial. | Qassim Regional Dental Center | Ongoing | Articaine | 3 | 607-43-7809 | Qassim Regional Dental Center,The One Clinic (Buraydah) |
| An open label, multi-center asciminib roll-over study to assess long-term safety in patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment. | Novartis | Ongoing | ABL001 (Asciminib), Imatinib, Nilotinib, Bosutinib | 3 | CABL001A2001B | King Faisal Specialist Hospital and Research Center (Riyadh) |
| Palbociclib Combinations in HR+/HER2- Metastatic Breast Cancer Patients: A Non-Interventional Prospective Study on the Treatment Patterns & Clinical Outcomes in Africa Middle East (PRECIOUS) | pfizer | Ongoing | PALBOCICLIB | 4 | A5481150 | King Fahad Specialist Hospital (Dammam) , King Abdulaziz Medical City NG (Riyadh) , King Khalid University Hospital (Riyadh) |
Last update date: 06/10/2026 at 08:14 AM Saudi Arabia time
No feedback has been submitted for this page yet.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.